# A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

> **NCT02303782** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** OTX015
- **DRUG:** Vidaza (azacitidine)

## Key facts

- **NCT ID:** NCT02303782
- **Lead sponsor:** Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303782, "A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02303782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*